Medical device park

1. At a Glance

Promotion of Medical Device Parks (PMDP) is a Central Sector Scheme of the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, providing grants-in-aid to State Governments to create common infrastructure for cluster-based medical device manufacturing [S1][S2].
Designed to cut India's ~60% import dependence in medical devices, lower manufacturing cost, and complement the PLI Scheme for Medical Devices [S1][S2].
Examinable because it sits at the intersection of Atmanirbhar Bharat, health-security, and PLI ecosystem — frequently asked in Prelims (ministry/scheme matches) and Mains GS-III (industry, health).

2. Why in the News

PIB release dated 17 March 2026 confirmed that three Medical Device Parks are being established in Uttar Pradesh, Madhya Pradesh and Tamil Nadu; no fresh proposals are currently under DoP consideration [S1].
Updated import data tabled: medical-device imports rose to USD 8,822 million in FY 2024-25 from USD 6,242 million in FY 2020-21 [S1].

3. Background & Evolution

March 2020: Union Cabinet approved domestic-manufacturing push for medical devices including the parks scheme [S2].
Oct/Nov 2020: Scheme guidelines launched by then-Minister D.V. Sadananda Gowda along with Bulk Drug Parks scheme [S2].
2021: Scheme formally notified; tenure FY 2020-21 to FY 2024-25 [S2].
2022: Final approval (Rs. 100 cr each) to Himachal Pradesh, Madhya Pradesh, Tamil Nadu and Uttar Pradesh [S2].
March 2024: Union Health Minister inaugurated 13 greenfield medical-device manufacturing plants under PLI [S3].
March 2026: Scheme operational in only three States (UP, MP, TN) per latest PIB note [S1].

4. Core Static Facts

Nodal Ministry: Ministry of Chemicals & Fertilizers → Department of Pharmaceuticals [S1].
Scheme type: Central Sector Scheme (grants-in-aid to States) [S2].
Outlay: ₹400 crore (FY 2020-21 to FY 2024-25) [S2].
Grant pattern: 70% of project cost for common infrastructure; 90% for NE & Hilly States; cap ₹100 crore per park [S2].
Selected States: UP, MP, TN (operational); HP was approved in 2022 but is not listed as operational in March 2026 [S1][S2].
Selection parameters: utility tariff, State incentives, park area, lease rate, connectivity, EoDB rank, technical manpower availability [S2].
Companion scheme — PLI for Medical Devices: outlay ₹3,420 crore; tenure FY 2022-23 to FY 2026-27; 5% incentive on incremental sales for 5 years; four target segments — (i) Cancer Care/Radiotherapy, (ii) Radiology & Imaging (incl. nuclear imaging), (iii) Anaesthetics & Cardio-Respiratory + Renal incl. ICU, (iv) Implants [S3].
PLI status: 32 applicants selected; 19 greenfield projects commissioned; ₹157.15 cr disbursed to 7 applicants till December 2025 [S3].
Import value FY 2024-25: USD 8,822 million (Electro-Medical Equipment dominant at USD 5,284 mn) [S1].

5. Multi-Dimensional Analysis

Economic: Targets import-substitution in a sector where ~60% domestic demand is met by imports; clustering reduces logistics/utility costs; PLI + Parks intended to attract anchor MNC investment in high-end equipment (MRI, CT, Linear Accelerator) [S1][S3].
Administrative / Federal: Land, utilities and SPV creation rest with State governments; Centre disburses milestone-linked grants — classic cooperative federalism model akin to Bulk Drug Parks [S2].
Strategic / Health Security: Reduces dependence on imports from China, US, Germany for critical-care equipment exposed during COVID-19 supply shock — original trigger for the scheme [S2].
Scientific & Technological: Parks to host testing labs, gamma irradiation, EMI/EMC, biomaterial testing as common facilities — bridging a key R&D gap for MSME device makers [S2].
Governance bottleneck: From four originally approved States, only three are progressing per March 2026 PIB note — illustrates execution lag in PLI/park-type schemes [S1].

6. Recent Developments (last 12-18 months)

17 March 2026: DoP confirmed three operational parks (UP, MP, TN); no new proposals pending [S1].
December 2025: ₹157.15 crore PLI incentive disbursed to 7 applicants; 28 applicants approved [S3].
March 2024: Union Minister inaugurated 27 greenfield Bulk Drug Park projects + 13 greenfield medical-device plants under PLI [S3].
FY 2024-25 imports climbed to USD 8.82 bn, up from USD 8.19 bn in FY 2023-24 — signalling persistent import dependence despite schemes [S1].

7. Prelims Hooks

Scheme "Promotion of Medical Device Parks" is implemented by Department of Pharmaceuticals (NOT Ministry of Health) [S1].
DoP sits under Ministry of Chemicals & Fertilizers [S1].
Total scheme outlay: ₹400 crore [S2].
Maximum grant per park: ₹100 crore [S2].
Centre's share: 70% (general) / 90% (NE & Hilly States) of common infrastructure cost [S2].
Operational parks (March 2026): Uttar Pradesh, Madhya Pradesh, Tamil Nadu [S1].
Himachal Pradesh received in-principle approval in 2022 alongside UP/MP/TN [S2].
PLI Medical Devices outlay: ₹3,420 crore; incentive rate 5% on incremental sales, 5-year period [S3].
PLI target segments: Radiotherapy; Radiology & Imaging; Anaesthetics/Cardio-Respiratory & Critical Care; Implants [S3].
Imports met ~60% of domestic consumption of medical devices [S1].
Electro-Medical Equipment is the single-largest import category (USD 5,284 mn in FY 2024-25) [S1].
Total medical-device imports FY 2024-25 = USD 8,822 million [S1].
Source for import data: DGCIS, Ministry of Commerce & Industry [S1].
PLI scheme tenure for medical devices: FY 2022-23 to FY 2026-27 [S3].

8. Mains Relevance

GS-III: Indian Economy — Growth & Development; Industrial Policy; Inclusive Growth; Science & Technology — indigenisation.
GS-II: Government policies for sectors — Health.
Plausible stems: 1. "Despite the PLI scheme and Medical Device Parks, India's import dependence in medical devices remains above 60%. Examine the structural reasons and suggest reforms." (GS-III) 2. "Discuss how cluster-based manufacturing (Bulk Drug Parks, Medical Device Parks) can re-shape India's pharmaceutical and med-tech value chain." (GS-III) 3. "Critically evaluate the role of cooperative federalism in implementation of Central Sector Schemes like the Promotion of Medical Device Parks." (GS-II)

9. Related Topics to Study Next

PLI Scheme for Medical Devices — direct companion incentive instrument [S3].
Bulk Drug Parks Scheme (₹3,000 cr) — twin cluster scheme by DoP [S2].
National Medical Devices Policy, 2023 — overarching policy umbrella.
CDSCO & Medical Devices Rules, 2017 — regulatory architecture.
Atmanirbhar Bharat Abhiyan — parent vision.
DGCIS (Directorate General of Commercial Intelligence & Statistics) — source body for trade data [S1].
PM-Ayushman Bharat Health Infrastructure Mission (PM-ABHIM) — demand-side stimulus for devices.
Pharmaceutical Export Promotion Council (Pharmexcil) — export institutional link.

10. Common Errors / Trap Areas

Confusing Department of Pharmaceuticals (M/o Chemicals & Fertilizers) with Ministry of Health & Family Welfare — devices regulation (CDSCO) is under MoHFW but parks/PLI are under DoP [S1].
Mixing ₹400 cr Parks outlay with ₹3,420 cr PLI outlay — distinct schemes [S2][S3].
Listing Himachal Pradesh as an operational park — initial 2022 approval, but the March 2026 PIB lists only UP, MP, TN as being established [S1][S2].
Treating "Medical Device Park" as part of Bulk Drug Parks Scheme — they are two separate notified schemes launched together in 2020 [S2].
Quoting 70% grant universally — NE & Hilly States get 90% [S2].

11. Sources

[S1] Medical device park — Department of Pharmaceuticals, PIB, 17 Mar 2026 — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2241167 — (tier: 1)
[S2] Scheme for "Promotion of Medical Device Parks" notified / Medical Device Parks updates, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1757662 ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=1848755 ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=1641517 — (tier: 1)
[S3] PLI Scheme for Promoting Domestic Manufacturing of Medical Devices & inauguration of greenfield plants, PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2085344 ; https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2010924 — (tier: 1)